Navigation Links
CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders
Date:6/16/2009

--Orally Active Enhancer of Human Nerve Growth Factor Has Demonstrated Promising Activity Preclinically--

--Broad Potential Applications Include Neuropathies, Alzheimer's and Huntington's Disease and Others--

RESEARCH TRIANGLE PARK, N.C., June 16 /PRNewswire/ -- CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced that it has obtained the rights to develop and market a novel agent for the prevention and treatment of neuropathies and neurodegenerative disorders. The drug candidate, CXB909, is a small molecule, orally active agent that enhances the effects of nerve growth factor (NGF). CeNeRx intends to initiate a Phase l trial of CXB909 for the treatment of chemotherapy-induced peripheral neuropathy (CIPN) later this year.

"Nerve growth factor has long been of interest as a potential therapy for neuropathies and neurodegenerative diseases, but recombinant NGF lacks key qualities needed for successful CNS drugs," said Dr. Daniel Burch, Executive Vice President of R&D and Chief Medical Officer of CeNeRx. "In preclinical studies, our small molecule agent CXB909 has been shown to increase the action of native NGF, but without the pharmacokinetic and administration challenges of recombinant NGF. Most notably, CXB909 crosses the blood brain barrier, has a long half-life and is orally available. The preclinical data for this agent is very promising, and we look forward to assessing it in the clinic for neuropathic and neurodegenerative conditions that currently have no treatment options."

CXB909 is a downstream enhancer of the effects of nerve growth factor, an endogenously produced neurotrophic factor that is important for the function and survival of several types of neurons. Both Alzheimer's disease and Huntington's disease involve the degeneration of certain neurons, and n
'/>"/>

SOURCE CeNeRx BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
2. CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study
3. CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)
4. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
5. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
7. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
8. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
9. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
10. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
11. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... SANTA CLARA, Calif. , Oct. 22, 2014 /PRNewswire/ ... today announced the introduction of the cQUB™-1 (cQuest Ultrasound ... cQUB white-label ultrasound systems designed and manufactured by Cephasonics ... brand name and model number. Cephasonics will be showcasing ... 2014 being held this week in Chongqing, ...
(Date:10/22/2014)... , October 22, 2014 Investor-Edge ... Inc. (NASDAQ: FOLD ), Progenics Pharmaceuticals Inc. ... THLD ), Idera Pharmaceuticals Inc. (NASDAQ: ... Free research on these five companies can be accessed ... 21, 2014, the NASDAQ Composite ended at 4,419.48, up ...
(Date:10/22/2014)... N.J. , Oct. 22, 2014   ... a world-renowned leader in the field of infertility, ... approach to embryonic screening. The research abstract, released ... for Reproductive Medicine (ASRM) meeting in ... (CCS) and single gene defect (SGD) pre-implantation genetic ...
Breaking Medicine Technology:Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3
... -- Pharmaceutical company Hatchtech Pty Ltd has completed treatment ... confirm the efficacy of its novel head lice treatment ... the efficacy, safety and tolerability of two dose levels ... The trial consists of treating 132 healthy subjects with ...
... LYNBROOK, N.Y., Aug. 31, 2011 Auxilium Pharmaceuticals, Inc. ... and BioSpecifics Technologies Corp. (NASDAQ: BSTC ), ... all pending litigation between the Companies and announced plans ... and human and canine lipoma as well as to ...
Cached Medicine Technology:Hatchtech Completes Treatment Phase of 2b Clinical Trial of New-Generation Head Lice Treatment Deovo™ 2Hatchtech Completes Treatment Phase of 2b Clinical Trial of New-Generation Head Lice Treatment Deovo™ 3Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 2Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 3Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 4Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 5Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 6Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 7Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 8
(Date:10/22/2014)... Springfield, Va. (PRWEB) October 22, 2014 For ... way to make money; it’s an extension of her life’s ... her latest venture as the owner of FirstLight HomeCare, make ... , “It’s important to me that my work makes a ... always harbored an entrepreneurial spirit, so after much research, I ...
(Date:10/22/2014)... Shriners Hospitals for Children® and UK ... current location of Shriners Hospitals for Children - Lexington ... the University of Kentucky Albert B. Chandler Hospital. The ... owned and operated by Shriners Hospitals for Children, and ... and their families well into the future. , “The ...
(Date:10/22/2014)... With the Affordable Care Act (ACA) open enrollment period ... for Research (AIR) finds that three out of four Americans ... 42 percent say they are not likely or only somewhat ... coverage. , The AIR survey found wide gaps in Americans’ ... correctly how much they owe for a routine doctor’s visit. ...
(Date:10/22/2014)... Healthcare professionals who are looking ... at home or on-the-go via laptops, tablets or ... new, premium Seminar-on-Demand CE courses. The new courses ... 2,000 hours of CE course offerings, allowing ... With such a diverse library, there’s something for ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Lintelus, Inc., ... Sr. Vice President of Sales, will be speaking on ... Meetings Technology Expo on October 28, at the Holiday ... hosting a booth as well as a Tech Demo ... Meeting can create a more engaging event experience. , ...
Breaking Medicine News(10 mins):Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2
... TUESDAY, March 8 (HealthDay News) -- Sleep deprivation may ... consider the potential consequences of financial risks, a new ... of sleep deprivation on 29 adult volunteers who were ... in the morning after a normal night of sleep ...
... OAK BROOK, Ill. March 8, 2011 In ... GIE: Gastrointestinal Endoscopy has published a special ... issue includes a study showing that colonoscopy has prevented ... that many more could have been prevented with more ...
... with epilepsy worry more than their physicians do about the ... a recent study. In a survey, patients with epilepsy ... concern on a list of 20 potential medical or social ... the frequency of responses among concerns recorded by physicians and ...
... brain can dramatically improve life for people with severe ... that causes painful, twisting neck muscle spasms according ... Jill Ostrem, MD and Philip Starr, MD PhD at ... with cervical dystonia can be treated with medications or ...
... , TUESDAY, March 8 (HealthDay News) -- The ... Tuesday to weigh the risks and benefits of those ... manufacturers contend, can help predict a person,s risk of ... medication. A panel of FDA advisers will look ...
... March 8 (HealthDay News) -- Coal-fired power plants emit ... to public health, warns a report released Tuesday by ... one week before the U.S. Environmental Protection Agency,s deadline ... pollution from coal-fired power plants. According ...
Cached Medicine News:Health News:Sleep Deprivation May Encourage Risky Decisions 2Health News:Colonoscopy linked to decrease in colorectal cancer deaths, but many more could have been prevented 2Health News:Colonoscopy linked to decrease in colorectal cancer deaths, but many more could have been prevented 3Health News:Colonoscopy linked to decrease in colorectal cancer deaths, but many more could have been prevented 4Health News:Epilepsy-linked memory losss worries more patients than doctors 2Health News:Epilepsy-linked memory losss worries more patients than doctors 3Health News:Epilepsy-linked memory losss worries more patients than doctors 4Health News:Brain implant surgeries at UCSF dramatically improve symptoms of debilitating condition 2Health News:FDA Weighs Pros, Cons of Home Genetic Testing 2Health News:FDA Weighs Pros, Cons of Home Genetic Testing 3Health News:Report Spells Out Harms of Coal Power Plants 2
... Blood Collection Needle consists of a BD ... safety shield aligned to the bevel-up position. ... Eclipse Blood Collection Needle has its safety ... attach a secondary safety accessory. Immediate, one-handed ...
37°C incubator for DianaGel cards....
ScanGel® Incubator...
... runs up to 12 mini gels under ... gels can be poured 12 at a ... former and Mini-PROTEAN 3 multi-casting chamber, eliminating ... Ready Gel precast gels offer the convenience ...
Medicine Products: